Walimu
Kampala, Uganda
Location status: Recruiting
NCT Number: NCT05917210
This cluster-randomized trial in Uganda will evaluate the effectiveness and implementation of a novel, peer-led TB education and counseling strategy to improve outcomes among persons with tuberculosis (TB) with and without HIV/AIDS and assess the social-behavioral mechanisms underlying the observed treatment effects.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Kampala, Uganda
Location status: Recruiting
Study Design
Aim 1. The investigators will conduct a parallel, cluster-randomized, hybrid Type 2, effectiveness-implementation trial at 16 sites in Uganda.
This clinical trials registration focuses on Aim 1.
In addition, we will pursue two additional non-interventional aims to better understand the implementation and outcomes of Aim 1:
Aim 2. Within the Aim 1 study, the investigators will also perform a mediation analysis of social and behavioral factors (i.e., TB knowledge, perceived social support, general self-efficacy, HIV/TB stigma) to identify causal mechanisms of impact.
Aim 3. The investigators will conduct nested quantitaive, qualitative, and mixed methods studies to assess the implementation fidelity and context of the peer-navigation strategy for TB-EC, including the following sub-aims:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants receive a peer-navigation strategy for TB education and counseling, including individual-level components such as peer navigator support, an illustrated TB-EC booklet with checklist, individualized adherence planning, and behavior-change messaging; and clinic-level components such as task-sharing with peer navigators, workflow restructuring, community of practice meetings, and implementation champions to support delivery.
Participants receive usual TB education and counseling delivered by healthcare workers, including individual-level components such as TB-HIV education using a flipchart and use of treatment supporters; and clinic-level components such as routine TB-EC delivery by healthcare workers.
Time frame: Up to 12 months after TB treatment initiation
Defined according to criteria from the World Health Organization as either:
The outcome will be assessed as the proportion of participants achieving TB treatment success based on program treatment records.
Time frame: At month 6 after ART initiation (+/- 30 days)
Among participants living with HIV and initiated on antiretroviral therapy (ART), ART retention will be defined as being (1) alive and (2) receiving ART, as evidenced by a documented ART medication pickup or documented ART supply at a clinical visit recorded in the on-site ART register or on the ART treatment card.
The outcome will be assessed as the proportion of participants living with HIV who are alive and receiving ART at 6 months after ART initiation.
Time frame: At month 5 after TB treatment initiation, ±30 days
Assessed using point-of-care urine colorimetric testing for isoniazid metabolites, conducted by trained on-site research assistants. A positive urine test indicates recent ingestion of isoniazid and will be used as an objective measure of adherence to isoniazid-containing TB therapy.
The outcome will be assessed as the proportion of participants with a positive urine test for isoniazid metabolites.
Time frame: At month 5 after TB treatment initiation, ±30 days
Among participants living with HIV and initiated on antiretroviral therapy (ART), ART adherence will be assessed using point-of-care urine testing for tenofovir using an enzyme-linked immunosorbent assay (ELISA), conducted by trained on-site research assistants. A positive urine test indicates recent ingestion of tenofovir and will be used as an objective measure of adherence to tenofovir-containing ART.
The outcome will be assessed as the proportion of participants living with HIV and initiated on ART with a positive urine tenofovir assay.
Contact information is provided by the study sponsor or research team.
Achilles Katamba, MBChB, DCH, MS, PhD
CONTACT
J. Lucian Davis, MD, MAS
CONTACT
Yale University
Other
Acronym: TEACH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07312266
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Manhiça, Maputo Province, Mozambique
View Trial DetailsNCT05868005
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Almería, Andalusia, Spain
View Trial DetailsNCT04520113
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Johannesburg, South Africa
View Trial DetailsNCT05282173
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Cape Town, Western Cape, South Africa
View Trial Details